US Patent Issued to Alnylam Pharmaceuticals on March 11 for "Modified RNA agents with reduced off-target effect" (Massachusetts Inventors)

ALEXANDRIA, Va., March 12 -- United States Patent no. 12,247,203, issued on March 11, was assigned to Alnylam Pharmaceuticals Inc..

"Modified RNA agents with reduced off-target effect" was invented by Shigeo Matsuda (Cambridge, Mass.), Mark K. Schlegel (Cambridge, Mass.), Maja Janas (Cambridge, Mass.), Vasant R. Jadhav (Cambridge, Mass.), Martin Maier (Cambridge, Mass.), Klaus Charisse (Cambridge, Mass.), Muthiah Manoharan (Cambridge, Mass.), Kallanthottathil Rajeev (Cambridge, Mass.) and Jayaprakash K. Nair (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Th...